IMNM
Immunome IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.44B
P/E Ratio
—
EPS
$-2.43
Beta
2.14
52W High
$27.65
52W Low
$5.76
50-Day MA
$22.41
200-Day MA
$16.27
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunome Inc
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.
Fundamentals
| Revenue (TTM) | $6.94M |
| Gross Profit (TTM) | $-170.34M |
| EBITDA | $-211.65M |
| Operating Margin | -3085.00% |
| Return on Equity | -52.10% |
| Return on Assets | -29.00% |
| Revenue/Share (TTM) | $0.08 |
| Book Value | $5.61 |
| Price-to-Book | 3.90 |
| Price-to-Sales (TTM) | 351.74 |
| EV/Revenue | 262.38 |
| EV/EBITDA | -0.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $113.13M |
| Float | $94.31M |
| % Insiders | 7.48% |
| % Institutions | 102.62% |
Analyst Ratings
Consensus ($35.54 target)
2
Strong Buy12
BuyData last updated: 4/8/2026